BG Medicine, a Waltham, MA-based developer of diagnostics technology, has withdrawn its second attempt at an initial public offering, after the deal failed to price, Dow Jones Newswires reports. Last week the firm set the targeted price range for its 4.75 million share IPO at $13 to $15 per share, giving it the potential to raise as much as $71.25 million. BG, which recently gained FDA clearance for its diagnostic test for chronic heart failure, also withdrew plans for an IPO in 2008.
Author: Erin Kutz
Erin Kutz has a background in covering business, politics and general news. She holds a bachelor’s degree in journalism from Boston University. Erin previously worked in the Boston bureau of Reuters, where she wrote articles on the investment management and mutual fund industries. While in college, she researched for USA Today reporter Jayne O’Donnell’s book, Gen Buy: How Tweens, Teens and Twenty-Somethings Are Revolutionizing Retail. She also spent a semester in Washington, DC, reporting Capitol Hill stories as a correspondent for two Connecticut newspapers and interning in the Money section of USA Today, where she assisted with coverage on the retail and small business beats. Erin got her first taste of reporting at Boston University’s independent student newspaper, as a city section reporter and fact checker and editor of the paper’s weekly business section.
View all posts by Erin Kutz
